These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 6614689)

  • 21. Penicillamine in Wilson's disease.
    Danks DM
    Lancet; 1982 Aug; 2(8295):435-6. PubMed ID: 6124819
    [No Abstract]   [Full Text] [Related]  

  • 22. Improvement of cardiovascular autonomic dysfunction following anti-copper therapy in Wilson's disease.
    Deguchi K; Sasaki I; Touge T; Tsukaguchi M; Ikeda K; Shimamura M; Urai Y; Watanabe S; Takeuchi H; Kuriyama S
    J Neurol; 2005 Apr; 252(4):495-7. PubMed ID: 15726258
    [No Abstract]   [Full Text] [Related]  

  • 23. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration).
    Hoogenraad TU; Koevoet R; de Ruyter Korver EG
    Eur Neurol; 1979; 18(3):205-11. PubMed ID: 477692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wilson's disease: current status.
    Yarze JC; Martin P; Muñoz SJ; Friedman LS
    Am J Med; 1992 Jun; 92(6):643-54. PubMed ID: 1605146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
    Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
    Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Wilson's disease (hepatolenticular degeneration) with penicillamine and low-copper diet.
    Goldstein NP; Tauxe WN; McCall JT; Gross JB; Randall RV
    Trans Am Neurol Assoc; 1969; 94():34-7. PubMed ID: 5374484
    [No Abstract]   [Full Text] [Related]  

  • 27. Diagnosis and treatment of Wilson's disease.
    Subramanian I; Vanek ZF; Bronstein JM
    Curr Neurol Neurosci Rep; 2002 Jul; 2(4):317-23. PubMed ID: 12044251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Control of the therapeutic prevention of copper uptake in the liver in Wilson's disease following oral administration of 64Cu].
    Günther K; Siegemund R; Lössner J; Kühn HJ
    Radiobiol Radiother (Berl); 1988; 29(2):226-9. PubMed ID: 3399664
    [No Abstract]   [Full Text] [Related]  

  • 29. Deterioration of Wilson's disease following the start of penicillamine therapy.
    Pall HS; Williams AC; Blake DR
    Arch Neurol; 1989 Apr; 46(4):359-61. PubMed ID: 2705894
    [No Abstract]   [Full Text] [Related]  

  • 30. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.
    Brewer GJ
    CNS Drugs; 2005; 19(3):185-92. PubMed ID: 15740174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The physiology of copper in man and its relation to Wilson's disease.
    Walshe JM
    Brain; 1967 Mar; 90(1):149-76. PubMed ID: 5336999
    [No Abstract]   [Full Text] [Related]  

  • 32. [On hepatolenticular degeneration (Wilson's disease). 3. Hepatic localization of Cu64: scintigraphic and dynamic study before and after treatment with BAL and D-penicillamine].
    D'Addabbo A; Damato VD; Germinario L; Campanella G; Boccuni N
    Acta Neurol (Napoli); 1971; 26(4):436-48. PubMed ID: 5132825
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents.
    Brewer GJ; Yuzbasiyan-Gurkan V; Johnson V; Dick RD; Wang Y
    J Am Coll Nutr; 1993 Feb; 12(1):26-30. PubMed ID: 8440814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two and half years of oral zinc sulphate therapy in an adult patient with Wilson's disease.
    Pasqualicchio M; Milanino R; Marrella M; Moretti U; Tomelleri G; Velo GP
    Pharmacol Res; 1989; 21 Suppl 1():151-2. PubMed ID: 2633173
    [No Abstract]   [Full Text] [Related]  

  • 35. Studies with radioactive copper (64Cu and 67Cu) in relation to the natural history of Wilson's disease.
    Osborn SB; Walshe JM
    Lancet; 1967 Feb; 1(7486):346-50. PubMed ID: 4163882
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative metabolism of copper and zinc in patients with Wilson's disease (hepatolenticular degeneration).
    McCall JT; Goldstein NP; Randall RV; Gross JB
    Am J Med Sci; 1967 Jul; 254(1):13-23. PubMed ID: 6027683
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.
    Merle U; Schaefer M; Ferenci P; Stremmel W
    Gut; 2007 Jan; 56(1):115-20. PubMed ID: 16709660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of Wilson's disease with Zincteral].
    Kuczyńska-Zardzewiały A; Rodo M; Członkowska A
    Neurol Neurochir Pol; 1988; 22(3):211-5. PubMed ID: 3221958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of Wilson's disease recovering from severe brain damage--special reference to trientine and D-penicillamine therapy].
    Ishitsu T; Chikazawa S
    No To Hattatsu; 1989 May; 21(3):294-6. PubMed ID: 2736129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.